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Abstract
This manuscript draws connections between chemoprophylaxis and the biomedical model of 
disease that emphasizes individual behavior. We argue that chemoprophylactic HIV interventions 
have limited utility at the population-level, and that structural interventions need to be prioritized. 
We use the recent CAPRISA 004 and iPrEx trials to (a) critique the utility of these trials from a 
public health perspective by highlighting the difference between efficacy and effectiveness, (b) 
apply an alternative theory of health behavior as a way to reorient the field toward the discussion 
of the need to employ structural interventions, and (c) examine two aspects of HIV prevention 
efforts – funding structures and iatrogenic effects of biomedical approaches – as a means of 
overcoming obstacles to more widespread adoption of structural interventions.
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Introduction
Articles regarding the CAPRISA 004 Trial and the iPrEx Trial, reporting the effectiveness 
and safety of a tenofovir based antiviral microbicide gel (the gel) and oral emtricitabine and 
tenofovir combination therapy (FTC-TDF), respectively, were published to much acclaim 
(Abdool Karim et al., 2010; Grant et al., 2010). CAP-RISA 004 found a 39% reduction in 
the incidence of HIV infection among women using the gel, and iPrEx found a 44% 
reduction in HIV incidence among men who have sex with men (MSM) using FTC-TDF. 
Both were double-blind, randomized, placebo controlled trials (RCT). These results were 
quite remarkable – none of the previous 11 microbicide trials had been able to demonstrate 
any effectiveness in preventing new HIV infection, and iPrEx was the first trial to provide 
evidence that oral pre-exposure prophylaxis can also reduce rates of HIV infection. Among 
many accolades, CAPRISA 004 results were featured in the keynote address at the 
International AIDS Conference, iPrEx was judged the top medical breakthrough of 2010 by 
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TIME Magazine, and both were reported on the front page of the New York Times (Dugger, 
2010; McNeil Jr., 2010; Park, 2010). While indeed path breaking work, we argue that these 
trials, heralded as watershed moments in the fight against HIV, are emblematic of the 
conflation of biomedicine and public health. We are over reliant on and place too much faith 
in the biomedical model of disease and the ability of biomedical technology to solve public 
health problems. Real progress in the fight against HIV requires reorganizing our thinking 
toward a more comprehensive approach that leverages both biological and social 
interventions as appropriate. We make our case by outlining three primary arguments.
First, we discuss the difference between efficacy and effectiveness by discussing aspects of 
the trials that limit the real world utility of the gel and FTC-TDF. We do this not because 
either were poorly conducted or bad science, but precisely because they are fitting examples 
of the problematic disconnect between a well conducted and analyzed RCT and real world 
public health application. Using specific details of the trials to anchor a general critique of 
biomedical and behavioral HIV interventions, we argue that common reasons underpin the 
failure of many individual-focused HIV interventions, indicative of an overreliance on the 
biomedical approach to prevention. Second, we apply an alternative theory of health 
behavior as a way to reorient the field toward the discussion of the need to employ structural 
interventions that prevent new HIV infections. However, we have long known HIV/AIDS is 
a socially patterned disease (Farmer, 1992; Shilts, 1987) and also recognize that structural 
interventions have previously been advocated (e.g., AIDS 2000:14(Suppl 1) is a special 
issue devoted to the topic). As such, our third argument presents a case for the importance of 
renewing efforts to facilitate these interventions. We discuss how our very funding structures 
reflect biomedical thinking while creating barriers to sustainable structural solutions and 
also discuss the iatrogenic effects of the biomedical approach to HIV interventions. This 
final argument is motivated by intransigence against implementing structural interventions. 
Given the announcement by the FDA to fast track approval of the gel (CONRAD, 2010), 
talk of a label change for Truvada (FTC-TDF’s brand name; Gilead Sciences, Foster City, 
CA) (Cohen, 2010), and continued investment in chemoprophylaxis trials (Cohen, 2010) a 
discussion of the feasibility and merits of high-risk versus structural interventions (defined 
below) is both warranted and timely.
Biomedical and public health approaches to disease
Before we pursue our three arguments, however, we first provide a brief overview of 
biomedical and public health approaches as a historical lens through which to ground our 
critique, and define several terms we use throughout the discussion. In this paper we draw a 
distinction between biomedical and public health approaches to disease. The biomedical 
approach has its roots in allopathic (western) medicine and is concerned with the individual 
– what caused this instance of disease, what can treat this individual, and what could have 
prevented this case from occurring? Clarke, Shim, Mamo, Fosket, and Fishman (2003) 
provide a useful overview of the history of biomedicalization. Medicalization, which began 
in the late 19th and continued through the 20th century, refers to the process in which 
allopathic medicine was embedded into various social realms. Bio-medicalization is a more 
recent phenomenon and refers specifically to the reconstitution and extension of 
medicalization through emergent forms of technoscience (a term referring to the inextricable 
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nature of scientific research from its practical application). Central to our arguments here, 
biomedicalization entails a focus on the individual as the primary unit of analysis as well as 
an increasing reliance on and expectation that technology will solve an expanding array of 
conditions defined as medical problems.
A public health approach to disease, however, is oriented toward populations and aggregates 
of individual health states – what causes rates of disease and how do we prevent disease 
from occurring in populations? Public health originated as a critique of the relationship 
between political economic systems and the health of populations (Waitzkin, 2007). 
However, biomedical thinking has permeated public health, as embodied by the Black Box 
era of epidemiology in which focus is given to individual risk factors and individual 
outcomes within populations (Susser & Susser, 1996a). One example of this influence is the 
emergence of individual autonomy as a goal of public health (Munthe, 2008). Here 
autonomy refers to providing opportunities for individuals to improve their own health either 
through information or technology while respecting an individual’s choice of whether or not 
to take advantage of said opportunity. In response to the Black Box era of epidemiology, 
equality has also emerged as a goal of public health (Munthe, 2008). This concern for how 
health is distributed among population subgroups can be seen in attempts to reinscribe 
public health with more sociologically oriented theories of disease causation (Diez-Roux, 
1998; Krieger, 1994; McMichael, 1999; Pearce, 1996; Susser & Susser, 1996b). So while we 
have seen an explosion of research into the social determinants of health (Kaplan, 2004) the 
extent to which public health is indeed focused on population health is debated and far from 
complete (Bourgois, 2002).
Drawing upon various literatures we employ several related but distinct terms in this 
manuscript. We use agency when referring to an individual’s freewill and decision making 
capacity. We refer to structures, on the other hand, to describe patterned social relationships 
(e.g., group affiliation), resources (e.g., capital accumulation), and institutions (e.g., 
government). Accordingly, we use the term structural intervention to refer to efforts that 
target the aforementioned entities in order to influence health, usually by means of 
facilitating health-promoting behavior or hindering health-harming behavior. Individual 
interventions, on the other hand, target agency; these interventions ask the individual to alter 
behavior without modifying structures that may promote or constrain behavior. We highlight 
two forms of individual interventions in the context of HIV: 1) interventions that target 
behavior and 2) interventions that target biological pathways of HIV infection. Structural 
interventions are more difficult to categorize, but have included targets ranging from income 
distribution to gender norms (e.g., Pronyk et al., 2006). We situate these intervention 
strategies within the framework offered by Geoffrey Rose (1985). He distinguishes between 
individual-level interventions aimed at high-risk groups that offer advice or medication to 
prevent individual instances of disease, and population-level interventions aimed at 
structures that serve as determinants of the distribution of disease to lower the mean level of 
disease within populations.
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Efficacy versus effectiveness – limitations of chemoprophylaxis and 
individual intervention
Following others we define the efficacy of an intervention as the reduction in risk associated 
with full and complete implementation of an intervention, and the effectiveness of an 
intervention as the reduction in risk as implemented (Institute of Medicine, 2008; Steckler & 
McLeroy, 2008; Stein, 1990). Efficacy then is an intrinsic property of the particular 
intervention (e.g., yearly rate of pregnancy among women who use condoms perfectly is 
2%). But effectiveness depends on the context into which an intervention is introduced (e.g., 
not all women use condoms correctly or consistently; yearly rates of pregnancy among 
women who exhibit “typical” condom use is 15%) (Trussell, 2007). Conceptually the upper 
limit of an intervention’s effectiveness is its efficacy, and quite often there is a considerable 
gap between the two. We argue there are two reasons underlying this gap. The most often 
acknowledged and debated reason concerns the conditions of the trials in which intervention 
efficacy is established. However, the second (underappreciated) reason concerns the nature 
of the interventions themselves.
Both trial protocols include interventions that address behavioral and biologic risk factors. 
These interventions have the potential to make the adherence estimates, and hence the 
reported efficacy of the gel and FTC-TDF, rest within their upper limits. To illustrate, both 
studies included frequent HIV counseling and testing during enrollment. In CAPRISA 004, 
a “comprehensive adherence support program assisted participants with the mechanics of 
applicator use, timing and dosing, avoidance of gel sharing and incorporation of gel use into 
their daily routines” (Abdool Karim et al., 2010; pg 1169). iPrEx diagnosed and treated 
symptomatic and asymptomatic sexually transmitted infections (STIs) in study subjects and 
their partners (Grant et al., 2010). Additionally, behavioral interventions (e.g., individualized 
motivational interviewing (MI), risk-reduction counseling) were used in both studies to 
assist participants in overcoming obstacles to gel/pill use.
As a matter of equipoise it was appropriate to include these behavioral components. As STIs 
increase the probability of HIV transmission (Fleming & Wasserheit, 1999), treating STIs 
may decrease HIV incidence in the social network of study participants (Though there is 
conflicting evidence regarding the effect of STI control interventions on HIV infection (Ng, 
Butler, Horvath, & Rutherford, 2011), ethical concerns would dictate their treatment 
regardless). The results (Table 2 (Abdool Karim et al., 2010), and Fig. 4 and Table S8 (Grant 
et al., 2010)) also show that the efficacy of the gel and FTC-TDF is a function of adherence. 
A review of MI interventions revealed MI can increase condom use and reduce risky sexual 
behaviors (Dunn, Deroo, & Rivara, 2001). And though evidence is not yet definitive, several 
studies suggest that MI might have both a direct and indirect effect on HIV medication 
adherence (Golin et al., 2006; Parsons, Rosof, Punzalan, & Di Maria, 2005). Furthermore, 
though RCTs are adept at building confidence in causal relationships, they often lack an 
ability to generalize these relationships to other populations because of self-selection into 
the RCTs. People that agree to participate in an RCT of HIV chemoprophylaxis may be less 
likely to engage in sexual risk behaviors and more likely to adhere to a prescribed regimen 
than individuals that do not agree to participate (e.g., Shoptaw et al., 2008). Though it is 
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difficult to quantify this bias it seems improbable that individuals most likely to engage in 
high-risk behavior are adequately represented in either (or any) study.
By virtue of their research design, these studies can isolate the unique effect of the gel/FTC-
TDF but they cannot isolate the effect of the interaction between the gel/FTC-TDF and the 
previously mentioned components that presumably would not accompany real world 
dissemination. (Ultimately this is a technical issue inherent in social science research 
surrounding the ability of a study to claim causal inference and the construct validity of a 
manipulated intervention.) Most troubling, however, is the preoccupation with “imperfect” 
behavior as the reason underlying the failure of biomedical intervention, a view that 
trivializes and ignores the nature of the failure itself – if only people were compliant our 
“perfect” intervention would have worked. Ironically, it is this very perspective which 
continues to privilege incomplete biomedical solutions. Some advocate for scaling up of 
combined behavioral and biomedical interventions as a means to maximize prevention 
efforts (e.g., Buchbinder & Liu, 2011; Padian, Buvé, Balkus, Serwadda, & Cates, 2008; Piot, 
Bartos, Larson, Zewdie, & Mane, 2008). However, continuing to neglect fundamental 
questions of human behavior will produce disappointing results in both the short and long 
term.
Figure 2 of each manuscript show Kaplan–Meier estimates of time to HIV infection for both 
the intervention and placebo arms (Abdool Karim et al., 2010; Grant et al., 2010). In 
CAPRISA 004 the difference in HIV incidence between the microbicide arm and placebo 
arm was quickly apparent with a 50% lower incidence of HIV among the women using the 
gel 12 months into the trial. However, over the course of the study the benefit associated 
with the microbicide waned and by 30 months there was only a 39% difference in incidence 
between the two arms. While estimates over time are not presented for iPrEx, the figure does 
show a trend where the large gap between FTC-TDF and placebo in weeks 84–108 
converges in weeks 120–132. Without additional data we can do little more than speculate as 
to what is responsible for these trends. However, a similar waning of intervention effects 
over time have been noted in large, controlled, HIV behavior change prevention trials 
(Coates, Richter, & Caceres, 2008). The reduction of effects over time across these studies 
leads us to be wary of how any meaningful population-level effect could be sustained. 
Though our ability to maintain intervention-facilitated behavior change has advanced 
greatly, these effects do diminish over time (Ory, Lee Smith, Mier, & Wernicke, 2010). 
Researchers who study behavior change also cite the importance of changing environments 
in order to maintain these effects (e.g., Toobert, Strycker, Glasgow, Barrera, & Angell, 
2005).
Though often considered different classes of interventions, both behavioral and biomedical 
interventions are products of biomedical thinking as they rely on the individual to be 
successful. With the exception of certain strategies (e.g., vaccination and circumcision), the 
majority of these strategies require continual adherence. And though the gel and FTC-TDF 
might arguably be seen as refinements on condoms in that they circumvent aspects of 
behavior that impede proper use – the gel is female controlled and PrEP can provide a 
biological barrier in the absence of condoms – they are both still individual health behaviors 
in their own right. We contend that there are limits to what individually focused 
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interventions, including chemoprophylaxis and behavioral modification, can achieve 
precisely because of the difficulty of implanting individually based interventions. The 
history of HIV interventions, however, has overwhelmingly focused on the biomedical and 
behavioral (Coates et al., 2008; Merson, O’Malley, Serwadda, & Apisuk, 2008; Padian et al., 
2008). There is, even if only implicit, a disconnect between individually focused 
interventions and the complexity of human behavior – even at the beginning of the epidemic, 
before scientists identified the virus that causes AIDS, we knew condoms could prevent new 
infections. Still, in that period of heightened fear and death among the MSM community in 
the United States, not everyone used condoms (Shilts, 1987). Rather than focus on refining 
biomedical interventions that are less efficacious than condoms, and potentially less 
effective, we should endeavor to understand the reasons underlying the gap between efficacy 
and effectiveness for both pragmatic public health and ethical reasons.
Having argued that the gap between the efficacy and effectiveness of an intervention is 
driven by not just the conditions of the trials but by the nature of the interventions 
themselves it becomes necessary to explore this disconnect in order to elucidate avenues for 
intervention. In the following section we utilize an alternative theory of health behavior 
through which to promote the importance of structural interventions.
An alternative theory of health behavior – implications for intervention 
strategies
An orientation primarily concerned with the autonomy of individuals might naturally focus 
on efficacy over effectiveness, as it lacks sufficient concern about aggregate levels of health. 
Arguably this orientation would also guide research efforts toward individual solutions to 
ameliorate individual risk factors. Because biomedical interventions are so well poised to 
address these individual risk factors, it may be largely why they are privileged in our 
research questions. This disconnect can be seen in the case of the gel. Twenty years ago an 
influential commentary called for the creation of a microbicide gel in order to empower 
women to protect themselves rather than rely on condom negotiations with their male 
partners (Stein, 1990). The logic being, though condoms are nearly 99% efficacious per use 
they cannot always be used since females negotiating condom use inverts the logic of male 
domination. Therefore, though less efficacious, a method that relies on a woman for 
implementation can be used more often and thus has the potential to prevent more 
transmissions at the population-level. This is the basis for infectious disease control – 
intervening on the components that make up the reproductive rate (R0), here the risk of 
transmission per contact, ultimately decreases the population-level incidence (Zenilman, 
2007). However, the article never questioned the logic of male domination or if the same 
paradigm might inhibit use of a gel. Male domination was taken for granted and by 
extension assumed to be immutable. This privileges biomedical intervention as the solution 
rather than interrogating the sociologic reasons underpinning the need to empower women 
and situating biomedical interventions as part of the solution.
This is not meant to demean the author of the commentary, discourage calls for innovation, 
or ignore interventions that have resulted in the empowerment of women in the last two 
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decades. Rather, we invoke this example because other interventions do not receive the same 
level of funding, attention or acclaim that chemoprophylaxis has. Furthermore this is a 
concrete example of the ways in which biomedical thinking myopically creates solutions to 
health problems. We find Cockerham’s (2005) “health lifestyle theory” a particularly useful 
alternative theory of health behavior to think about these issues. Drawing on Weber and 
Bourdieu (among others) Cockerham constructs a paradigm to explain why individuals 
engage in various health behaviors. Structures (e.g., class, gender, race) probabilistically 
shape life chances (e.g., what schools you go to) but also influence one’s socialization 
experiences (e.g., culture), which influence the choices one makes. The interplay of life 
chances and life choices create one’s dispositions to engage in behavior. Critical to our 
arguments, this model demonstrates why it’s difficult to change individual behavior with 
education or technology – one’s disposition to act is deeply rooted in life history. Behaviors 
hold salience to individuals, particularly behaviors as intimate as sex or drug use. The theory 
also highlights the power that structures exert at various times and levels on the creation and 
maintenance of health behaviors. Therefore, while we recognize that health behavior is 
ultimately determined by individual choice (i.e., agency), those choices are a function of 
very real structural constraints. Structures that rest outside of individual control make it 
easier or harder to engage in particular health behaviors. It is easier to recognize the 
constraints certain structures produce (e.g., user fees on antiretroviral (ARV) medication 
adherence) and somewhat more difficult to enumerate others (e.g., norms and desires 
surrounding unprotected sex). Health lifestyle theory acknowledges the importance of 
behavior as a determinant of health, but likewise acknowledges that individual behavior is 
rarely wholly determined by individuals. This logic should serve to renew an impetus toward 
creating and disseminating structural interventions. In addition to modifying those structures 
that influence health outcomes, we also argue that structural intervention promotes the 
possibility for increased individual agency. Structural change is not at odds with individual 
autonomy, but it may facilitate it.
Of course, structural interventions are hardly the magic bullet to public health problems, but 
they represent an important step forward. What is particularly attractive about structural 
interventions is that they can directly influence the likelihood of engaging in behavior by 
making it harder or easier. The promise of structural intervention on population health rests 
among those individuals who want to engage in healthy behaviors but who live in a context 
where their choices are constrained (e.g., I want to exercise but there’s nowhere to run), and 
also among individuals whose behaviors is largely dictated by convenience (e.g., it is easier 
to bike to work than to drive and find parking). We also recognize that people engage in 
health-damaging behaviors all the time despite numerous structures in place to prevent their 
use. Tobacco use is a notable example where individuals have to actively overcome a variety 
of barriers to smoke. We would not argue that there is one structure that needs to be targeted 
to unleash healthy human behavior, rather research will need to unearth the complex of 
structures producing health behaviors (e.g., Bourgois & Schonberg, 2008). Furthermore, 
because structural interventions will almost always succumb to strong individual agency to 
do otherwise, achieving the greatest population effect rests in accommodating strategies that 
target individual behaviors as well. For this reason it is not uncommon for authors to call for 
layered approaches to HIV prevention strategies that include both behavioral and structural 
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interventions (e.g., Coates et al., 2008; Piot et al., 2008; Rotheram Borus, Swendeman, & 
Chovnick, 2009).
The lack of clarity surrounding structural interventions is also of consequence. Even when 
articles articulate how structural conditions influence HIV risk, or summarize the state of 
structural interventions, too often are scaled-up individual-level campaigns conflated with 
structural interventions (Parker, Easton, & Klein, 2000; Poundstone, Strathdee, & Celentano, 
2004). Scaling up individually based interventions still fundamentally relies on changing 
individual actions to mitigate risk without altering the context in which decisions are made 
and therefore does not represent a structural intervention (McLaren, McIntyre, & 
Kirkpatrick, 2010). We acknowledge that one component of this problem rests with 
inconsistent characterizations of what constitutes structural intervention. Earlier in the paper 
we defined structural interventions as those efforts that target one of those entities we 
described, but understandably others have generated lists different from our own. While we 
cannot resolve this issue of definitions, we are less interested in deciding precisely where the 
line is drawn and more in putting forward a vital point: a behavioral intervention does not de 
facto become a structural intervention by virtue of being implemented on a large scale. And 
though several excellent extant typologies of structural interventions exist (Blankenship, 
Bray, & Merson, 2000; Blankenship, Friedman, Dworkin, & Mantell, 2006; Des Jarlais, 
2000; Gupta, Parkhurst, Ogden, Aggleton, & Mahal, 2008; Sumartojo, 2000) inaction 
persists, which seems to indicate insufficient will rather than insufficient knowledge.
Many have studied the structural drivers of HIV infection among heterosexuals in South 
Africa and MSM in the United States. Though a comprehensive review of structural 
constraints that influence HIV transmission is beyond the scope of this manuscript, the 
following examples are indicative of behavioral constraints created by social structures, 
placing populations at risk of HIV infection. In South Africa high levels of HIV knowledge 
among high-risk populations fail to prevent infection because costs, wait times and 
stigmatizing behavior by service providers result in reluctance to access health services 
(Parry, Petersen, Carney, Dewing, & Needle, 2008). Reduced spending on public sector 
health care across the globe and imposed user fees as part of cost recovery plans led to 
dramatic decreases in preventive and primary care services, including STI treatment and 
distribution of ARVs, all of which have dramatic consequences for HIV transmission 
(Kalipeni, Craddock, Oppong, & Ghosh, 2004; Stein, 2008). Within the United States MSM 
face prejudice, discrimination, and stigma associated with same-sex behavior, the stress from 
which has been demonstrated to adversely influence mental health (Hatzenbuehler, 
McLaughlin, Keyes, & Hasin, 2010; Meyer, 1995) and sexual health behaviors (Diaz, Ayala, 
& Bein, 2004). Young MSM who experience rejection from family because of their sexual 
orientation are less likely to consistently use condoms during sex, more likely to abuse drugs 
(Ryan, Huebner, Diaz, & Sanchez, 2009), and may resort to commercial sex work to support 
themselves (i.e., “survi val sex “) (Gangamma, Slesnick, Toviessi, & Serovich, 2008).
Renewing efforts to facilitate structural interventions
One under-examined factor in our failure to sufficiently implement structural interventions 
lies in how we fund interventions in the United States. The National Institutes of Health 
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overwhelmingly focuses funding on biomedical approaches to the exclusion of structural 
(and even behavioral) research (Bertozzi, Laga, Bautista-Arredondo, & Coutinho, 2008; 
Kaplan, 1998). Approximately 95% of the trillion dollars the United States spends on health 
goes to direct medical services, with only 5% being allocated to population - approaches to 
prevention (McGinnis, Williams-Russo, & Knickman, 2002). Another aspect of funding lies 
in the organization of how monies are allocated. We overwhelmingly concentrate both 
intellectual and financial resources on individual outcomes rather than shared exposures or 
horizontal service integration (Rotheram-Borus et al., 2009). HIV is not the only health 
concern for South Africans or MSM. Identifying and influencing common causes of various 
health concerns would be a more efficient approach to public health in terms of allocating 
resources and promoting health.
Others have argued against criticisms (such as ours), which state that public health has an 
inappropriate pre-occupation with identifying mechanisms and solutions that exist at the 
individual-level (Rothman, Adami, & Trichopoulos, 1998). One of their arguments is that 
scientists should be able to pursue science for the sake of science and that a “downstream” 
focus has produced useful interventions. In general we agree with this sentiment, however in 
the case of HIV prevention there are iatrogenic effects of the individualistic research 
enterprise that weaken this particular critique.
As discussed above, there is a clear rationale behind the development of both the gel and 
FTC-TDF, though we highlight how a different theoretical orientation would alter the 
approach one might take to solving each issue. However, several externalities require 
consideration. Regarding FTC-TDF, we must be mindful that MSM at highest risk of HIV 
infection may also be least likely to adhere to a regular regimen. A study of HIV-positive 
MSM found that active substance use was negatively associated with ARV adherence 
(Malta, Strathdee, Magnanini, & Bastos, 2008). While we carefully interpret the gel’s 
effectiveness it does have the potential to fill an unmet need. Nevertheless, we caution that 
those women who are already most at risk of HIV infection by virtue of living in an 
environment which constrains their behavioral choices may be most vulnerable to misuse of 
the gel if they misunderstand how to use the microbicide, or believe that it is 100% 
efficacious. Worse yet is the possibility they are coerced into using it in lieu of condoms, or 
subversive use subjects them to retributive domestic violence. These specific situations have 
not been documented though others have documented the complex nexus of disadvantaged 
social status, drug use, gender based violence and sexual risk behaviors among South 
African women (e.g., Morojele, Brook, & Kachieng’a, 2006; Sawyer, Wechsberg, & Myers, 
2006).
Another frequently cited concern regarding chemoprophylaxis is the potential for an 
increase in risky sexual behavior, or behavioral disinhibition (Eaton & Kalichman, 2007). 
We agree this possibility is troubling. Investigators should remain vigilant of this possibility 
though we highlight how an approach targeting structural constraints to engage in health 
behaviors may mitigate this concern.
The logic underpinning pre-exposure chemoprophylaxis as an HIV prevention tool, however, 
is less clear to us. One editorial went so far as to describe iPrEx as “proof of concept.” 
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(Michael, 2010) Considering only 36% of infected individuals in low and middle income 
countries are on ARV treatment (UNAIDS, 2010) it’s hard to imagine covering entire 
populations with ARVs as a prevention tool. Given the known potential for antiviral 
resistance to develop (McGowan, 2010), the side effects of long term use of ARVs, the 
difficulty ensuring the effectiveness of condoms (which are far more efficacious), and that 
we have yet to even provide ARVs for all HIV-positive people, it’s difficult not be skeptical 
of the underlying the exploration and continued funding of chemoprophylaxis (Cohen, 2010; 
Michael, 2010). If we are truly serious about using ARVs in any sort of preventive capacity, 
their greatest utility would be realized by ensuring that all individuals living with HIV 
receive appropriate medication. We can simultaneously promote the health of HIV-positive 
persons while reducing the likelihood for transmission through suppressing viral loads 
(Cohen et al., 2011; Donnell et al., 2010; Quinn et al., 2000). Given that this approach was 
lauded as the 2011 scientific breakthrough of the year by Science magazine (Cohen, 2011), 
we hope this is an area in which structural and biomedical intervention can work in concert 
to reduce new infections.
Biomedical interventions have a long history in the fight against HIV (Padian et al., 2008). 
That we have not had more success is frustrating, with some suggesting that we need to get 
drugs to phase 2B/3 trials sooner (McGowan, 2010). Unfortunately there is little reflection 
on how these clinical trials are conducted. For pragmatic reasons, researchers need to 
conduct all clinical trials in populations with high HIV incidence rates. Quite literally then 
we have been experimenting on vulnerable populations for 30 years. We acknowledge the 
existence of risk groups (by identifying populations that experience high HIV incidence) but 
ignore the reasons that underpin the high rates of disease the trials are designed to stop. This 
shifts responsibility for infection from the social conditions an individual is subject to, to the 
individual’s behavior. The result, though unintentional, is to perpetuate methodological 
individualism reinforcing forms of symbolic violence that further stigmatize and subjugate 
already marginalized populations – symbolic violence, a concept developed by Bourdieu, 
refers to the imposition of categories of thought and perception by the dominant on the 
dominated. Analyzing the world through these categories, the dominated perceive the social 
order as just and attribute the source of individual failings to the individual. To illustrate, 
some have explicitly invoked the high-risk strategy in the case of FTC-TDF. MSM deemed 
to be at high-risk (as determined by a prediction model and clinical judgment) would be 
preferentially offered prescriptions (Myers & Mayer, 2011). This confessional approach to 
prescribing PrEP – whereby MSM are required to admit to engaging in “high-risk” 
behaviors to health professionals – serves to admonish while at the same time labels the 
individual and reinforces stigma, which serves to facilitate risk of infection in the first place 
(Bourgois, 1998). Moreover, there is little attention given to the omnipresence of HIV 
clinical trails in constructing hegemonic notions of MSM as promiscuous and plagued by 
HIV, or how this may contribute to senses of complacency (Rausch, Dieffenbach, Cheever, 
& Fenton, 2011) or fatalism (Grov & Parsons, 2006) among MSM populations. There are 
likely similar effects in African populations.
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Reflections on biomedical and structural interventions in public health
Looking back twenty years provides an opportunity to ask ourselves some very important 
questions. We must remember that the potential virtue of the microbicide never rested solely 
in its efficacy, but rather was conceptualized to be a useful tool in the fight against HIV 
because of its potential for real world effectiveness; when did we lose sight of this? While an 
intervention with any efficacy is indicated in an acute outbreak, in South Africa the HIV 
prevalence among antenatal clinic attendees increased from less than 1% in 1990 to over 
20% by 1998 (Department of Health, 2005) and in 2008 an estimated 17% of the adult 
population was living with HIV (UNAIDS, 2009). In the United States, young MSM 
represent the only group in which the number of new infections motives has increased since 
2006; MSM accounted for 61% of all new infections in 2009 (Prejean et al., 2011). The 
sheer magnitude of the HIV epidemic and its perseverance dictates we consider alternatives.
Looking to the future, we should be cognizant that the funding priorities and acclaim 
awarded to biomedical research compared to population health approaches sets a precedent 
that requires scrutiny. The lack of population health approaches may largely be a result of 
the structures in place used to fund research, where resources are allocated by individual 
outcomes, rather than shared exposures. As a pragmatic science, it is public health’s 
imperative to figure out the best ways to improve the health of the public rather than solely 
pursue what’s being funded. The continued limited utility of individually based interventions 
requires a rethinking of our funding schemes as well as the incentive structure in academia 
(Katz, 2008; Levins, 2010), a reflexive monitoring of the favored lines of inquiry (Navarro, 
2005) which requires advocacy by the public health enterprise for variety of the types of 
projects that get funded, and a personal commitment by researchers to interrogate their 
position of privilege and – to invoke Gutierrez – exercise the “preferential option for the 
poor” (Binford, 2004; Gutierrez, 1973).
Finally, we must realize that structural interventions are not inherently perfect. Behavioral 
interventions are not exclusively subject to the problems we’ve outlined. Structural 
interventions can also be implemented poorly, and as uncomfortable as the possibility may 
be, can also result in iatrogenic effects. For example, others have called for the 
decriminalization of HIV transmission as a way to improve public health by normalizing 
condom behavior, increasing testing rates and decreasing HIV-related stigma (Burris & 
Cameron, 2008).
Winning the fight against the HIV epidemic will require intervention in a variety of areas. 
We laud any advancement that may reduce new infections, though we highlight the need for 
innovations that are just as concerned with the social environment as a determinant of the 
HIV epidemic as we are those innovations that target the biological mechanism of HIV 
infection. Remaining mindful of social contexts also highlights the importance of future 
studies that will need to examine the real world effectiveness of chemoprophylaxis alongside 
efforts to increase its efficacy, and reminds us to consider iatrogenic effects of these (and all) 
research approaches. There is much extant work on the structural drivers of HIV infection 
and a key challenge moving forward will be to translate this knowledge base into practice. 
Population-level interventions will need to target these structures in order to influence the 
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epidemiology of the HIV epidemic. Additional work needs to also be done on understanding 
emerging and changing trends in structural drivers. CAPRISA 004 and iPrEx represent 
important steps forward, but while we celebrate these milestones in the biomedical we need 
to remain vigilant in our recognition that HIV is also a socially patterned disease. As such, 
we need to act accordingly and also invest intellectual and material resources in those 
interventions that alter social structures as well.
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